TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31138247

Group type: EXPERIMENTAL
Intervention: 5% albumin infusion (10 ml/kg) administered slowly (180 min)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 5% albumin infusion (10 ml/kg) administered rapidly (30 min)
Number of subjects: 64
Study: 28376836

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (no acupuncture) group
Number of subjects: 100
Study: 25837245

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long duration exercise (60 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short duration exercise (10 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute mountain sickness (AMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 0
Study: 24184066

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention (MBI) for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 27
Study: 22746358

Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle training (PFMT) once weekly for 12 months (Group A, n=42)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard care/training (Group B, n=43)
Number of subjects: 85
Study: 19638646

Group type: EXPERIMENTAL
Intervention: Cytological surveillance every six months in primary care (n=2223)
Number of subjects: 4439

Group type: COMPARATOR
Intervention: Referral for colposcopy (n=2216)
Number of subjects: 4439

Group type: EXPERIMENTAL
Intervention: Cytological surveillance
Number of subjects: 4439

Group type: COMPARATOR
Intervention: Immediate colposcopy
Number of subjects: 4439
Study: 17334706

Group type: EXPERIMENTAL
Intervention: Large neutral amino acids (LNAA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15142218

Group type: EXPERIMENTAL
Intervention: Once a day toothcleaning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Once in 2 days toothcleaning
Number of subjects: 20
Study: 11422148

Group type: EXPERIMENTAL
Intervention: Oral montelukast (10 mg tablet for adults, 5 mg chewable tablet for children)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (beclomethasone 200 microg twice daily for adults, 100 microg or equivalent three times daily for children)
Number of subjects: 436
Study: 9727891

Group type: EXPERIMENTAL
Intervention: 200 mg troglitazone
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 400 mg troglitazone
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Troglitazone in open-label extension
Number of subjects: 222
Study: 8051884

Group type: EXPERIMENTAL
Intervention: Stimulus size 3
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Stimulus size 5
Number of subjects: 49
Study: 1821247

Group type: EXPERIMENTAL
Intervention: Intervention group (reduction of serum antimuscarinic activity)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 34
Study: 6941465

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 170

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 170
Study: 31469243

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8mg/kg intravenous infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept 50mg subcutaneous injections
Number of subjects: 0
Study: 30777017

Group type: EXPERIMENTAL
Intervention: Framed intervention (prevention perspective)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Framed intervention (promotion perspective)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Neutral framing (control)
Number of subjects: 111
Study: 28634121

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (300 mg, twice daily)
Number of subjects: 0
Study: 25028283

Group type: EXPERIMENTAL
Intervention: Playing‐2‐gether (n = 89)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Education-as-usual control condition (n = 86)
Number of subjects: 175
Study: 24301236

Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A (ABO) at doses ranging from 120 to 250 U
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High dose of ABO in the perioral area
Number of subjects: 90
Study: 21332412

Group type: EXPERIMENTAL
Intervention: Barnidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 19584187

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (0.012 mg/kg every second day, approximately 2.5 IU)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 158
Study: 17582635

Group type: EXPERIMENTAL
Intervention: Slow-releasing drug-eluting stents (sirolimus and paclitaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rapid-releasing drug-eluting stents (sirolimus and paclitaxel)
Number of subjects: 0
Study: 15198763

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (0.8 mg)
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (0.4 mg)
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (0.8 mg)
Number of subjects: 2219

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Both misoprostol groups
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Overall perception of medical abortion
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Future abortion preferences
Number of subjects: 2219
Study: 11394732

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Combination of bupropion SR and nicotine patch
Number of subjects: 893

Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 893

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893
Study: 9555354

Group type: EXPERIMENTAL
Intervention: Intensive management group (educational sessions)
Number of subjects: 53
Study: 8072263

Group type: EXPERIMENTAL
Intervention: AN69 membranes during anaphylactoid reactions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AN69 membranes during symptom-free sessions
Number of subjects: 22

Group type: COMPARATOR
Intervention: CuprophanR membranes
Number of subjects: 22

Group type: COMPARATOR
Intervention: HemophanR membranes
Number of subjects: 22

Group type: COMPARATOR
Intervention: PolysulfoneR membranes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AN69 membranes (specific patient with hypersensitivity)
Number of subjects: 22
Study: 2895214

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study: 31509849

Group type: EXPERIMENTAL
Intervention: RCS‐01 (25 × 10^6 cultured, autologous cells derived from anagen hair follicle non‐bulbar dermal sheath)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCS‐01
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryomedium (placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Needle penetration without injection (placebo)
Number of subjects: 0
Study: 30912296

Group type: EXPERIMENTAL
Intervention: Green tea (GT) treatment for 4 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hot water (HW) ingestion for 4 months (after GT treatment in Grp1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hot water (HW) ingestion for 4 months (before GT treatment in Grp2)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Green tea (GT) treatment for 4 months (after HW ingestion in Grp2)
Number of subjects: 200
Study: 28712591

Group type: EXPERIMENTAL
Intervention: SPIOMET (spironolactone 50 mg/d, pioglitazone 7.5 mg/d, metformin 850 mg/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SPIOMET
Number of subjects: 36

Group type: COMPARATOR
Intervention: OC (ethinylestradiol-levonorgestrel)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 36
Study: 25130321

Group type: EXPERIMENTAL
Intervention: Medications associated with weight gain
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Early age of onset of bipolar symptoms
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: More time spent depressed
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Less time spent manic/hypomanic
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Longer duration of illness
Number of subjects: 482
Study: 23230066

Group type: COMPARATOR
Intervention: 0 mg/kg/day iron supplementation (placebo)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day iron supplementation
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day iron supplementation
Number of subjects: 285

Group type: COMPARATOR
Intervention: Normal birth weight controls
Number of subjects: 285
Study: 21563029

Group type: EXPERIMENTAL
Intervention: Leger equation (E1, 1988)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Brewer equation (E2, 1988)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: 20 m shuttle run test
Number of subjects: 313

Group type: COMPARATOR
Intervention: Laboratory test
Number of subjects: 313
Study: 18837739

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (750 mg daily)
Number of subjects: 22
Study: 16557483

Group type: EXPERIMENTAL
Intervention: SJW herb extract (LI‐160) 300 mg once daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SJW herb extract (LI‐160) 300 mg twice daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SJW herb extract (LI‐160)
Number of subjects: 28
Study: 14535628

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day) for 2 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 18
Study: 10735496

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) 0.1 mg subcutaneously on days 1, 3, 5, 15, 17, and 19 of each 28-day cycle along with 100 mg/m(2) cisplatin and 600 mg/m(2) cyclophosphamide
Number of subjects: 148

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m(2) and cyclophosphamide 600 mg/m(2)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Cisplatin and cyclophosphamide
Number of subjects: 148
Study: 8723395

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors (class effect)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors (various trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study: 1414156

Group type: EXPERIMENTAL
Intervention: Danazol 150 mg/day for patients under 15 years and 300 mg/day for older patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3908619

Group type: EXPERIMENTAL
Intervention: Polyadenylic-polyuridylic acid (poly(A).poly(U)) as adjuvant treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 300
Study: 31085320

Group type: EXPERIMENTAL
Intervention: Bilateral CCA filter placement
Number of subjects: 25
Study: 27832366

Group type: EXPERIMENTAL
Intervention: Whey protein drink (PRO 23.9 ± 3.6 g protein)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dextrose drink (CHO 26.5 ± 3.8 g carbohydrate)
Number of subjects: 15
Study: 26794704

Group type: EXPERIMENTAL
Intervention: 10% CP (Opalescence PF; Ultradent Products, Inc)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10% CP (Power Bleaching 10%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 15% CP (Opalescence PF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 16% CP (Power Bleaching 16%)
Number of subjects: 50
Study: 24861925

Group type: EXPERIMENTAL
Intervention: Autonomy-Supportive Language (ASL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlling Language (CL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral Language (NL)
Number of subjects: 0
Study: 22289570

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (20 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Micellar casein (20 g)
Number of subjects: 14
Study: 19833613

Group type: EXPERIMENTAL
Intervention: Customized aspheric IOL (Acri.Smart 36A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Zero aberration IOL (Acri.Smart 46LC)
Number of subjects: 43
Study: 18049943

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Soy phytoestrogens 55 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16255136

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for gastric cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant therapy for gastric cancer
Number of subjects: 0
Study: 12145148

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fish oils (4 g/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined treatment with atorvastatin and fish oils
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10103335

Group type: EXPERIMENTAL
Intervention: 10 mg of Ritalin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 17.5 mg of Ritalin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 7.5 mg of Adderall
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 12.5 mg of Adderall
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8852543

Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg once daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 25
Study: 2177180

Group type: EXPERIMENTAL
Intervention: Wheat bran ingestion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 6773725

Group type: EXPERIMENTAL
Intervention: High-dose insulin (1.0 U/kg/h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-dose insulin (0.1 U/kg/h)
Number of subjects: 32
Study: 31696371

Group type: EXPERIMENTAL
Intervention: Vaginally delivered HIV prevention product
Number of subjects: 395

Group type: COMPARATOR
Intervention: Daily-use product
Number of subjects: 395

Group type: COMPARATOR
Intervention: Insertion by finger
Number of subjects: 395
Study: 30732853

Group type: EXPERIMENTAL
Intervention: Mentored simulation training (ST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (before ST)
Number of subjects: 20
Study: 28094033

Group type: EXPERIMENTAL
Intervention: saline+10μg/ml‐1 vancomycin (vanco group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 20
Study: 25753445

Group type: EXPERIMENTAL
Intervention: Family-led, trained caregiver-delivered, home-based rehabilitation intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 104
Study: 23406477

Group type: EXPERIMENTAL
Intervention: Divalproate extended release (DVA‐ER)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Amitriptyline (AMT)
Number of subjects: 300
Study: 20718824

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Microemulsified cyclosporin (CYA)
Number of subjects: 66
Study: 19470865

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy (FS) for saphenous insufficiency
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy (FS)
Number of subjects: 1025
Study: 17907494

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond Multi‐Purpose (three‐step etch‐and‐rinse)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: One‐Step (two‐step etch‐and‐rinse)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (two‐step self‐etching)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Xeno III (one‐step self‐etching)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Prolonged irradiation time for all adhesives
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Delayed adhesive application (after 24 hours or 14 days)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (Unbleached enamel powder)
Number of subjects: 4
Study: 15383107

Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories (two x 100 mg)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo suppositories (Anusol)
Number of subjects: 133
Study: 11195739

Group type: EXPERIMENTAL
Intervention: 1 g cefepime
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 g cefepime
Number of subjects: 30
Study: 9703380

Group type: EXPERIMENTAL
Intervention: GHRH infusion (0.33 microg/kg every 90 min for 3 days)
Number of subjects: 19
Study: 7927120

Group type: EXPERIMENTAL
Intervention: Suriclone 0.4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Suriclone 0.4 mg + Imipramine 75 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2789922

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 25 mg folinic acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of 25 mg folinic acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Total (‐)‐folates excreted in urine after both routes
Number of subjects: 12
Study: 788759

Group type: EXPERIMENTAL
Intervention: Hydrallazine (75‐150 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phentolamine (60‐120 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31743196

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3 cycles of 5‐minute ischemia and 5‐minute reperfusion in right upper limb with cuff pressure at 30 kPa (225 mm Hg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham RIPC (cuff not inflated)
Number of subjects: 140
Study: 29351538

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole 960 mg tablets p.o. administered 14 and 2 hours before catheter removal
Number of subjects: 100

Group type: COMPARATOR
Intervention: No antibiotics administered
Number of subjects: 100
Study: 26105567

Group type: EXPERIMENTAL
Intervention: START, then CTAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: START alone
Number of subjects: 0
Study: 23537231

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 160

Group type: COMPARATOR
Intervention: Progressive muscle relaxation training
Number of subjects: 160
Study: 21739910

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasonography (CDU)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multislice computed tomography angiography (MSCTA)
Number of subjects: 75
Study: 19951427

Group type: EXPERIMENTAL
Intervention: Dimeticone 4% lotion
Number of subjects: 72

Group type: COMPARATOR
Intervention: Alternative product (not specified)
Number of subjects: 72
Study: 16671929

Group type: EXPERIMENTAL
Intervention: Infrequent reinforcement (mean 20 s interval)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Frequent reinforcement (mean 2 s interval)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Infrequent reinforcement
Number of subjects: 56
Study: 12771924

Group type: EXPERIMENTAL
Intervention: High-risk HPV-DNA test (HC2; Hybrid Capture 2)
Number of subjects: 8466

Group type: EXPERIMENTAL
Intervention: Routine cytology
Number of subjects: 8466

Group type: COMPARATOR
Intervention: Randomly selected control group (negative findings on both cytology and HPV test)
Number of subjects: 8466

Group type: EXPERIMENTAL
Intervention: Negative HPV-test result
Number of subjects: 8466
Study: 10649147

Group type: EXPERIMENTAL
Intervention: Intervention group with counseling materials
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 457
Study: 9345543

Group type: EXPERIMENTAL
Intervention: Immediate pointing to the most recent target
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pointing to the previous target
Number of subjects: 8

Group type: COMPARATOR
Intervention: Visual detection of the target without overt responses
Number of subjects: 8
Study: 7506145

Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg twice daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Naproxen (500mg twice daily)
Number of subjects: 53
Study: 3521255

Group type: EXPERIMENTAL
Intervention: Benzydamine HCl
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 29708773

Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW) intervention
Number of subjects: 479

Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 479
Study: 27565018

Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and a P2Y12 inhibitor (either clopidogrel or ticagrelor)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Triple antithrombotic therapy with warfarin, a P2Y12 inhibitor (either clopidogrel or ticagrelor), and low-dose aspirin (for 1 or 3 months, depending on stent type)
Number of subjects: 2500
Study: 25000528

Group type: EXPERIMENTAL
Intervention: Palmitate treatment (300 µM) for three days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Palmitate treatment (300 µM) for one day
Number of subjects: 11
Study: 22878697

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19910834

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition
Number of subjects: 107

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 107
Study: 18350631

Group type: EXPERIMENTAL
Intervention: Spironolactone plus propranolol (n = 18: Group B)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Propranolol alone (n = 17: Group A)
Number of subjects: 35
Study: 15770205

Group type: EXPERIMENTAL
Intervention: 20 Gy/5 fractions (arm A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 16 Gy/2 fractions (arm B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 100
Study: 14651242

Group type: EXPERIMENTAL
Intervention: Resin cement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zinc-oxide-eugenol-free cements
Number of subjects: 48